Elucidation of factors enhancing the expression of CD20 and
thereby efficiency of CD20 monoclonal antibodies through
epigenetic drug screening of resistant CLL cells

a 2020

Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ et. al.

Basic information

Original name

Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

Authors

KOZLOVÁ, Veronika (203 Czech Republic, belonging to the institution), Aneta LEDEREROVÁ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, belonging to the institution)

Edition

XVIII. International Workshop on CLL, Edinburgh, Skotsko, 2020

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.280

RIV identification code

RIV/00216224:14740/20:00115243

Organization unit

Central European Institute of Technology

ISSN

UT WoS

000534385400182

Keywords in English

CD20; CLL cells

Abstract

V originále

In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

MUNI/A/1105/2018, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Acronym: VýDiTeHeMA VI)

Investor: Masaryk University, Category A

NV15-33561A, research and development project

Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie

Citovat

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK and Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In XVIII. International Workshop on CLL, Edinburgh, Skotsko. 2020. ISSN 1042-8194.

@proceedings{1609558,
   author = {Kozlová, Veronika and Ledererová, Aneta and Mančíková, Veronika and Mayer, Jiří and Pospíšilová, Šárka and Doubek, Michael and Šmída, Michal},
   booktitle = {XVIII. International Workshop on CLL, Edinburgh, Skotsko},
   keywords = {CD20; CLL cells},
   language = {eng},
   title = {Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells},
   url = {https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1732667},
   year = {2020}
}

TY  - CONF
ID  - 1609558
AU  - Kozlová, Veronika - Ledererová, Aneta - Mančíková, Veronika - Mayer, Jiří - Pospíšilová, Šárka - Doubek, Michael - Šmída, Michal
PY  - 2020
TI  - Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
KW  - CD20
KW  - CLL cells
UR  - https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1732667
N2  - In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy
ER  -

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK and Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In \textit{XVIII. International Workshop on CLL, Edinburgh, Skotsko}. 2020. ISSN~1042-8194.

Detailed Information on Publication Record